Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR -0.23%88 Cash Ratio is 3.59 as of Mar. 2026, which is 21% below its 10-year median of 4.52. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.20 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 975 Drug Manufacturers companies, United Therapeutics ranks better than 88.51% on this metric.
United Therapeutics has a Cash Ratio of 3.59. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for United Therapeutics's Cash Ratio or its related term are showing as below:
UTHR'
s Cash Ratio Range Over the Past 10 Years
Min: 1.33 Med: 4.52 Max: 8.82
Current: 3.59
During the past 13 years, United Therapeutics's highest Cash Ratio was 8.82. The lowest was 1.33. And the median was 4.52.
UTHR's Cash Ratio is ranked better than 88.51% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs UTHR: 3.59
United Therapeutics (NAS:UTHR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
United Therapeutics Cash Ratio Related Terms
United Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a Cash Ratio of 3.59 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on United Therapeutics and its competitors. This is 21% below median its historical median of 4.52. Over the past decade, United Therapeutics' Cash Ratio has ranged from 1.33 to 8.82. According to the industry distribution chart, United Therapeutics ranks #112 out of 975 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is United Therapeutics' Cash Ratio too high?
United Therapeutics' current Cash Ratio of 3.59 is 21% below median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 8.82. The Drug Manufacturers industry median Cash Ratio is 0.61. United Therapeutics' value of 3.59 is 488.5% above this industry median. Based on the distribution chart, United Therapeutics ranks #112 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Cash Ratio compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #112 out of 975 companies for Cash Ratio. This places United Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.61. United Therapeutics' value of 3.59 is 488.5% above this benchmark. Historically, United Therapeutics' own Cash Ratio has ranged from 1.33 to 8.82 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 0.61, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Cash Ratio of 3.59 is 488.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Cash Ratio is 3.59, which is 21% below median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.20, compared to a current price of $528.31 — trading 36.4% above its estimated fair value. The current Cash Ratio is 3.59, which is 21% below median its 10-year median of 4.52 and 488.5% above the Drug Manufacturers industry median of 0.61. United Therapeutics' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Cash Ratio is 3.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $528.31 is trading 36.4% above its estimated GF Value™ of $387.20.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
Cash Ratio: 3.59 (21% below median its 10-year median of 4.52)
GF Value™: $387.20 vs. price of $528.31 (36.4% above fair value)
Industry Position: 488.5% above the Drug Manufacturers median (#112 of 975)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
